<bill session="115" type="h" number="1223" updated="2017-07-29T07:16:33Z">
  <state datetime="2017-02-27">REFERRED</state>
  <status>
    <introduced datetime="2017-02-27"/>
  </status>
  <introduced datetime="2017-02-27"/>
  <titles>
    <title type="short" as="introduced">OPEN Act</title>
    <title type="short" as="introduced">OPEN Act</title>
    <title type="short" as="introduced">Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017</title>
    <title type="short" as="introduced">Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act to authorize an extension of exclusivity periods for certain drugs that are approved for a new indication for a rare disease or condition, and for other purposes.</title>
    <title type="display">OPEN Act</title>
  </titles>
  <sponsor id="412250"/>
  <cosponsors>
    <cosponsor id="412713" joined="2017-04-03"/>
    <cosponsor id="400616" joined="2017-02-27"/>
    <cosponsor id="412672" joined="2017-03-08"/>
    <cosponsor id="400124" joined="2017-03-08"/>
    <cosponsor id="400640" joined="2017-03-24"/>
    <cosponsor id="400142" joined="2017-03-01"/>
    <cosponsor id="412511" joined="2017-03-24"/>
    <cosponsor id="412290" joined="2017-03-01"/>
    <cosponsor id="400245" joined="2017-06-23"/>
    <cosponsor id="412445" joined="2017-07-28"/>
    <cosponsor id="400654" joined="2017-02-27"/>
    <cosponsor id="400659" joined="2017-06-27"/>
    <cosponsor id="412568" joined="2017-03-16"/>
    <cosponsor id="400285" joined="2017-03-08"/>
    <cosponsor id="412606" joined="2017-03-16"/>
    <cosponsor id="412302" joined="2017-07-12"/>
    <cosponsor id="412443" joined="2017-05-22"/>
    <cosponsor id="412699" joined="2017-06-12"/>
    <cosponsor id="412186" joined="2017-06-28"/>
    <cosponsor id="412695" joined="2017-03-01"/>
    <cosponsor id="412514" joined="2017-06-28"/>
    <cosponsor id="400414" joined="2017-07-11"/>
    <cosponsor id="412410" joined="2017-04-03"/>
  </cosponsors>
  <actions>
    <action datetime="2017-02-27">
      <text>Introduced in House</text>
    </action>
    <action datetime="2017-02-27" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2017-03-03">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral"/>
    <committee activity="Referral" code="HSIF14" subcommittee="Health" name="House Energy and Commerce"/>
  </committees>
  <relatedbills>
    <bill relation="unknown" session="115" type="s" number="1509"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative remedies"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug therapy"/>
    <term name="Food and Drug Administration (FDA)"/>
    <term name="Government information and archives"/>
    <term name="Intellectual property"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2017-02-27T05:00:00Z" status="Introduced in House">Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017 or the OPEN Act

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Department of Health and Human Services (HHS) to extend by six months the exclusivity period for a drug or biological product approved by the Food and Drug Administration (FDA) when the product is additionally approved to prevent, diagnose, or treat a new indication that is a rare disease or condition (also known as an orphan disease).

HHS may revoke an extension if the application submitted to the FDA for the new indication contained an untrue material statement.

HHS must notify the public of products that receive this extension and patents related to those products.

Products may recieve only one extension under this bill. Extensions under this bill are in addition to other extensions.

The bill applies only to products approved after enactment of this bill for a new indication that is a rare disease or condition.</summary>
  <committee-reports/>
</bill>
